Teriparatide (Forteo)

M.D. Anderson Cancer Center · FDA-approved active Small molecule

Teriparatide (Forteo) is a Parathyroid hormone analog Small molecule drug developed by M.D. Anderson Cancer Center. It is currently FDA-approved for Osteoporosis in postmenopausal women at high risk for fracture, Osteoporosis in men at high risk for fracture, Glucocorticoid-induced osteoporosis. Also known as: Forteo, PTH, Parathyroid Hormone, FORTEO.

Teriparatide is a recombinant parathyroid hormone analog that stimulates osteoblasts to increase bone formation and remodeling.

Teriparatide is a recombinant parathyroid hormone analog that stimulates osteoblasts to increase bone formation and remodeling. Used for Osteoporosis in postmenopausal women at high risk for fracture, Osteoporosis in men at high risk for fracture, Glucocorticoid-induced osteoporosis.

At a glance

Generic name	Teriparatide (Forteo)
Also known as	Forteo, PTH, Parathyroid Hormone, FORTEO
Sponsor	M.D. Anderson Cancer Center
Drug class	Parathyroid hormone analog
Target	PTH1 receptor (parathyroid hormone 1 receptor)
Modality	Small molecule
Therapeutic area	Endocrinology / Bone Metabolism
Phase	FDA-approved

Mechanism of action

Teriparatide mimics the action of endogenous parathyroid hormone (PTH) by binding to PTH1 receptors on osteoblasts, promoting bone cell proliferation and differentiation. This leads to increased bone turnover with a net gain in bone mass, particularly in trabecular bone. Unlike other osteoporosis agents that primarily inhibit bone resorption, teriparatide actively stimulates new bone formation.

Approved indications

• Osteoporosis in postmenopausal women at high risk for fracture
• Osteoporosis in men at high risk for fracture
• Glucocorticoid-induced osteoporosis

Common side effects

• Injection site reactions (erythema, pain, swelling)
• Nausea
• Dizziness
• Headache
• Leg cramps
• Hypercalcemia

Key clinical trials

• A Study of B-3E07 and Forsteo® in Healthy Adult Female Participants (PHASE1)
• Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo (PHASE1)
• Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture (NA)
• Effect of Teriparatide, Vibration and the Combination on Bone Mass and Bone Architecture in Chronic Spinal Cord Injury (PHASE2)
• Effect of Mechanical Loading With PTH on Cortical Bone (PHASE4)
• Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis (NA)
• Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid (PHASE4)
• Novel Combination Therapy for Osteoporosis in Men (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Teriparatide (Forteo) CI brief — competitive landscape report
• Teriparatide (Forteo) updates RSS · CI watch RSS
• M.D. Anderson Cancer Center portfolio CI

Frequently asked questions about Teriparatide (Forteo)

What is Teriparatide (Forteo)?

Teriparatide (Forteo) is a Parathyroid hormone analog drug developed by M.D. Anderson Cancer Center, indicated for Osteoporosis in postmenopausal women at high risk for fracture, Osteoporosis in men at high risk for fracture, Glucocorticoid-induced osteoporosis.

How does Teriparatide (Forteo) work?

Teriparatide is a recombinant parathyroid hormone analog that stimulates osteoblasts to increase bone formation and remodeling.

What is Teriparatide (Forteo) used for?

Teriparatide (Forteo) is indicated for Osteoporosis in postmenopausal women at high risk for fracture, Osteoporosis in men at high risk for fracture, Glucocorticoid-induced osteoporosis.

Who makes Teriparatide (Forteo)?

Teriparatide (Forteo) is developed and marketed by M.D. Anderson Cancer Center (see full M.D. Anderson Cancer Center pipeline at /company/m-d-anderson-cancer-center).

Is Teriparatide (Forteo) also known as anything else?

Teriparatide (Forteo) is also known as Forteo, PTH, Parathyroid Hormone, FORTEO.

What drug class is Teriparatide (Forteo) in?

Teriparatide (Forteo) belongs to the Parathyroid hormone analog class. See all Parathyroid hormone analog drugs at /class/parathyroid-hormone-analog.

What development phase is Teriparatide (Forteo) in?

Teriparatide (Forteo) is FDA-approved (marketed).

What are the side effects of Teriparatide (Forteo)?

Common side effects of Teriparatide (Forteo) include Injection site reactions (erythema, pain, swelling), Nausea, Dizziness, Headache, Leg cramps, Hypercalcemia.

What does Teriparatide (Forteo) target?

Teriparatide (Forteo) targets PTH1 receptor (parathyroid hormone 1 receptor) and is a Parathyroid hormone analog.

Related

• Drug class: All Parathyroid hormone analog drugs
• Target: All drugs targeting PTH1 receptor (parathyroid hormone 1 receptor)
• Manufacturer: M.D. Anderson Cancer Center — full pipeline
• Therapeutic area: All drugs in Endocrinology / Bone Metabolism
• Indication: Drugs for Osteoporosis in postmenopausal women at high risk for fracture
• Indication: Drugs for Osteoporosis in men at high risk for fracture
• Indication: Drugs for Glucocorticoid-induced osteoporosis
• Also known as: Forteo, PTH, Parathyroid Hormone, FORTEO